Beacon Pharmaceuticals PLC introduced a noble and selective factor Xa inhibitor drug Rivaroxaban 10mg tablet under brand the name of Rivosis.

The company launched the product on August 17, 2021.

Rivosis (Rivaroxaban) is indicated for reducing stroke risk in patients of non-valvular atrial fibrillation, reducing recurrence risk of deep vein thrombosis & pulmonary embolism.

It is also indicated for the acutely ill patients suffering from prophylaxis of venous thromboembolism and for the Prophylaxis of DVT/PE patients after their hip or knee replacement surgery.

According to the National Guidelines on Clinical Management of Co

vid-19, Rivaroxaban is also indicated for thromboprophylaxis of Covid-19 patients with moderate to severe symptoms.

Rivaroxaban 10mg tablet is applicable for once in a day for 30 days, after seven days treatment with LMWH (Enoxaparin).